Coya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA) posted its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14, Zacks reports. The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million.

Coya Therapeutics Trading Up 0.4 %

Shares of NASDAQ:COYA traded up $0.03 during trading on Wednesday, reaching $6.48. 32,838 shares of the company traded hands, compared to its average volume of 97,353. The business’s fifty day moving average is $6.30 and its 200-day moving average is $6.49. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.42. The firm has a market capitalization of $108.19 million, a price-to-earnings ratio of -9.85 and a beta of 0.31.

Analysts Set New Price Targets

A number of research analysts have commented on COYA shares. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, February 6th. D. Boral Capital reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Tuesday.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.